These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36321415)

  • 41. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer.
    Chen R; Guo S; Yang C; Sun L; Zong B; Li K; Liu L; Tu G; Liu M; Liu S
    Int J Oncol; 2020 Apr; 56(4):932-944. PubMed ID: 32319562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.
    Lazarus P; Blevins-Primeau AS; Zheng Y; Sun D
    Ann N Y Acad Sci; 2009 Feb; 1155():99-111. PubMed ID: 19250197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tamoxifen Resistance: Emerging Molecular Targets.
    Rondón-Lagos M; Villegas VE; Rangel N; Sánchez MC; Zaphiropoulos PG
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
    Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
    Planas-Silva MD; Bruggeman RD; Grenko RT; Smith JS
    Exp Mol Pathol; 2007 Feb; 82(1):85-90. PubMed ID: 17046747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
    Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
    Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
    Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
    Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
    Ojo D; Wu Y; Bane A; Tang D
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
    Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
    Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
    Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
    Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer.
    Yu S; Wu R; Si Y; Fan Z; Wang Y; Yao C; Sun R; Xue Y; Chen Y; Wang Z; Dong S; Wang N; Ling X; Liang Z; Bi C; Yang Y; Dong W; Sun H
    Oncogene; 2024 Sep; 43(39):2901-2913. PubMed ID: 39164523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
    Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
    Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer.
    Lee J; Jeong JH; Jung JH; Kim WW; Lee SJ; Park JY; Park JY; Kang SH; Kim EA; Park JH; Chae YS; Park HY
    Oncology; 2019; 97(3):180-188. PubMed ID: 31330520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
    Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.